- Thinly traded micro cap Adamas Pharmaceuticals (ADMS +1.5%) heads north on light volume on the heels of its announcement of pooled results from two Phase 3 clinical trials evaluating ADS-5102 (amantadine) in patients with Parkinson's disease (PD). The data were presented at the American Academy of Neurology Annual Meeting in Boston.
- Pooled results from the EASE LID and EASE LID 3 studies were consistent with the original results from the trials that showed treatment with ADS-5102 produced a statistically significantly reduction in OFF time and a significant reduction in levodopa-induced dyskinesia (LID).
- ADS-5102 is an extended-release formulation of PD drug amantadine, originally approved by the FDA in November 2003 under the brand name Symmetrel, marketed by Endo Pharmaceuticals.
- Adamas' U.S. marketing application is currently under FDA review with an action date of August 24.
- Previously: Adamas Pharma's lead product candidate successful in late-stage LID study; shares up 43% premarket (Dec. 23, 2015)
- Now read: Adamas Pharmaceuticals (ADMS) Presents At 16th Annual Needham Healthcare Conference - Slideshow
Original article